Table 1. Characteristics of AML patients with intermediate-risk according to DNMT3A exon 23 mutation.
| No DNMT3A exon 23 mutation | DNMT3A exon 23 mutation | p | |
|---|---|---|---|
| Sex - no. | |||
| Male | 78 | 17 | 0.48 |
| Female | 77 | 22 | |
| Age - y | |||
| Median | 53 | 47 | 0.051 |
| Range | 18-65 | 20-63 | |
| WBC - G/L | |||
| Median | 14.6 | 52 | <0.0001 |
| Range | 0.8-356 | 1.0-250 | |
| Hb - g/dL | |||
| Median | 9.6 | 10.4 | 0.22 |
| Range | 4.3-16 | 4.8-13.2 | |
| Platelets - G/L | |||
| Median | 70 | 62 | 0.54 |
| Range | 5-964 | 8-814 | |
| FAB AML subtypes - no. | |||
| M0/M1/M2 | 4/43/45 | 0/3/6 | <0.0001 |
| M4 /M5 | 26/27 | 17/11 | |
| M6/M7 | 0/0 | 0/0 | |
| Unclassified | 10 | 1 | |
| Normal Karyotype no. (%) | 96 (62) | 27 (69) | 0.46 |
| Mutations - no. /total no. (%) | |||
| FLT3-ITD | 37/155 (24) | 17/39 (44) | 0.027 |
| FLT3-TKD | 3/62 (5) | 1/14 (7) | 0.57 |
| NPM1 | 49/155 (32) | 29/39 (74) | <0.0001 |
| CEBPA | 20/155 (13) | 2/39 (5) | 0.26 |
| IDH1 | 16/155 (10) | 8/39 (21) | 0.10 |
| IDH2 | 16/155 (10) | 5/39 (13) | 0.77 |
| KIT exon 17 | 2/155 (1) | 0/39 (0) | - |
| Complete response - no. (%) | 126/155 (81) | 34/39 (87) | 0.48 |
| Allogeneic SCT - no./total no. (%) | 40/155 (26) | 16/39 (41) | 0.075 |
| Autologous SCT - no./total no. (%) | 28/155 (18) | 7/39 (18) | 1.00 |
| Relapse - no./total no. (%) | 63/126 (50) | 14/34 (41) | 0.36 |
| 5-year survival (%) | 36.5 | 47.3 | - |
WBC, white blood cell count; FAB, French American British; SCT, stem-cell transplantation.